envarsus 4 mg retardtabletten - op90
chiesi farmaceutici s.p.a. (3198853) - tacrolimus 1 h<2>o - retardtablette - tacrolimus 1 h<2>o (32463) 4,08 milligramm
envarsus 1 mg retardtabletten - op90
chiesi farmaceutici s.p.a. (3198853) - tacrolimus 1 h<2>o - retardtablette - tacrolimus 1 h<2>o (32463) 1,02 milligramm
envarsus 1 mg retardtabletten - op30
chiesi farmaceutici s.p.a. (3198853) - tacrolimus 1 h<2>o - retardtablette - tacrolimus 1 h<2>o (32463) 1,02 milligramm
envarsus 0,75 mg retardtabletten - op60
chiesi farmaceutici s.p.a. (3198853) - tacrolimus 1 h<2>o - retardtablette - tacrolimus 1 h<2>o (32463) 0,765 milligramm
envarsus 4 mg retardtabletten - op30
chiesi farmaceutici s.p.a. (3198853) - tacrolimus 1 h<2>o - retardtablette - tacrolimus 1 h<2>o (32463) 4,08 milligramm
envarsus 0,75 mg retardtabletten - op90
chiesi farmaceutici s.p.a. (3198853) - tacrolimus 1 h<2>o - retardtablette - tacrolimus 1 h<2>o (32463) 0,765 milligramm
envarsus 1 mg retardtabletten - op60
chiesi farmaceutici s.p.a. (3198853) - tacrolimus 1 h<2>o - retardtablette - tacrolimus 1 h<2>o (32463) 1,02 milligramm
envarsus 0,75 mg retardtabletten - op30
chiesi farmaceutici s.p.a. (3198853) - tacrolimus 1 h<2>o - retardtablette - tacrolimus 1 h<2>o (32463) 0,765 milligramm
envarsus 4 mg retardtabletten - op60
chiesi farmaceutici s.p.a. (3198853) - tacrolimus 1 h<2>o - retardtablette - tacrolimus 1 h<2>o (32463) 4,08 milligramm
elfabrio
chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabry-krankheit - anderen verdauungstrakt und stoffwechsel-produkte, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).